Haemonetics (HAE) Tops Q2 EPS by 18c, Revenues Beat; Raises FY20 EPS Guidance Above Consensus
Tweet Send to a Friend
Haemonetics (NYSE: HAE) reported Q2 EPS of $0.87, $0.18 better than ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
